BioSyent
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2476 Argentia Rd Ste 402, Mississauga, O...Phone Number
(905) 206-0013Website
www.biosyent.comRevenue
$30.4 MillionStock Symbol
RXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About BioSyent
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.Explore more
BioSyent Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioSyent your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BioSyent recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at BioSyent
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when BioSyent launches new products
Click to see if BioSyent had a recent Job posting/layoffs
Check out if BioSyent is spiking on competitors!
BioSyent, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BioSyent has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once BioSyent has new funding data
Recommended Actions
Reach out to Masked Content who joined BioSyent as Masked Content
Find 3 more new buyers
Compare Similar Companies to BioSyent
Compare insights from companies similar to BioSyent, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioSyent is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioSyent is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioSyent.
BioSyent financials insights
Gather financial insights about BioSyent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$6.8M
BioSyent Tech Stack
A closer look at the technologies used by BioSyent
Most Recent Scoops
Earnings
reported that its international pharma business had a solid quarter and a very strong year with over 300% growth.
Sales, Pharmaceuticals, Acquisitions
Earnings
reported that Q4 2025 represented the company's 62nd consecutive profitable quarter. The company became profitable in mid-year 2010 and has been consistently profitable since then.
Earnings, Finance
Award
BioSyent announced that Faramax was named the number one oral iron supplement amongst doctors and pharmacists in Canada in April 2025.
Award, Pharmaceuticals
Earnings
paid a quarterly dividend on March 13th, representing a 10% increase compared to the prior year quarterly dividends. The dividend is now 5.5 cents per share, totaling 22 cents per share on a full-year basis.
Earnings, Finance
Divestiture
Divestitures, Sales, Finance
BioSyent News & Media
BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.BioSyent says Oral Science acquisition added nearly $3M in March sales
BioSyent says its acquisition of Oral Science contributed nearly $3 million in sales during March as the company expands its oral health business in Canada.BioSyent Declares Second Quarter 2026 Dividend
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifiesBioSyent Releases Financial Results for First Quarter 2026
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights include:
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding BioSyent
Sign Up For FreeTo access detailed company insights
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital an... Read More
